Acalabrutinib

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Acalabrutinib
File:Acalabrutinib.svg
Systematic (IUPAC) name
4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide
Identifiers
CAS Number 1420477-60-6
ChemSpider 36764951
Chemical data
Formula C26H23N7O2
Molecular mass 465.507 g/mol
  • CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
  • InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
  • Key:WDENQIQQYWYTPO-IBGZPJMESA-N

Acalabrutinib (rINN,[1] ACP-196) is an experimental anti-cancer drug and a 2nd generation BTK inhibitor[2] developed by Acerta Pharma.[3]

It is designed to be more selective (fewer side-effects) than ibrutinib.[2]

As of 2015 it is in late stage clinical trials for relapsed chronic lymphocytic leukemia. Interim results are encouraging : 95% overall response rate.[2][4]

It is also in another 20 clinical trials (alone and in combination) for various cancers.[4][5]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ 4.0 4.1 Acerta Pharma Announces Study Published in New England Journal of Medicine Demonstrates Acalabrutinib (ACP-196) Shows Marked Activity in Relapsed Chronic Lymphocytic Leukemia
  5. ↑ 21 studies found for: ACP-196

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Acalabrutinib&oldid=714929239"